Delving into the Latest Updates on Novartis Pharmaceuticals Australia Pty Ltd. with Synapse

Overview

Tags

Other Diseases

Nervous System Diseases

Neoplasms

Small molecule drug

Monoclonal antibody

Single-chain FV antibody fragment

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	16
Neoplasms	15
Immune System Diseases	14
Endocrinology and Metabolic Disease	12
Hemic and Lymphatic Diseases	12
Infectious Diseases	7

Top 5 Drug Type	Count

Small molecule drug	28
Monoclonal antibody	4
Non-degrading molecular glue	1
Therapeutic radiopharmaceuticals	1
siRNA	1

Top 5 Target	Count

VEGF-A(Vascular endothelial growth factor A)	2
ATP2A1 x SERCA2	1
β2-adrenergic receptor(Beta-2 adrenergic receptor)	1
P-sel(P-selectin)	1
PTGFR(Prostanoid FP receptor)	1

Background Siponimod is approved for use in people with secondary progressive multiple sclerosis (pwSPMS). An integrated digital platform, MSGo, was developed for pwSPMS and clinicians to help navigate the multiple steps of the pre-siponimod work-up. Objective To explore real-world onboarding experiences of siponimod amongst pwSPMS in Australia. Methods Retrospective, non-interventional, longitudinal, secondary analysis of data extracted from MSGo (20 April 2022). The primary endpoint was the average time for siponimod onboarding; secondary endpoints were adherence and sub-group analyses of variables influencing onboarding. Results Mixed-cure modelling estimated that 58% of participants ( N = 368, females 71%, median age of 59 years) registered in MSGo would ever initiate siponimod. The median time to initiation was 56 days (95% CI [47–59] days). Half of the participants cited ‘waiting for vaccination’ as the reason for initiation delay. Cox regression analyses found participants with a nominated care partner had faster onboarding (HR 2.1, 95% CI [1.5–3.0]) and were more likely to continue self-reporting daily siponimod dosing than were those without a care partner (HR 2.2, 95% CI [1.3–3.7]). Conclusions Despite the limitations of self-reported data and the challenges of the COVID-19 pandemic, this study provides insights into siponimod onboarding in Australia and demonstrates the positive impact of care partner support.

01 Jan 2024·Therapeutic Advances in Neurological Disorders

Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons

Article

Author: Barnett, Michael ; Merschhemke, Martin ; Butzkueven, Helmut ; Van der Walt, Anneke ; Drudge, Christopher ; McCombe, Pamela ; Walker, Rob ; Nelson, Morag ; Adlard, Nicholas ; Wong, Erin O. Y. ; Samjoo, Imtiaz A. ; Riley, Nicholas ; Haltner, Anja ; Broadley, Simon

Background: Evidence from network meta-analyses (NMAs) and real-world propensity score (PS) analyses suggest monoclonal antibodies (mAbs) offer a therapeutic advantage over currently available oral therapies and, therefore, warrant consideration as a distinct group of high-efficacy disease-modifying therapies (DMTs) for patients with relapsing multiple sclerosis (RMS). This is counter to the current perception of these therapies by some stakeholders, including payers. Objectives: A multifaceted indirect treatment comparison (ITC) approach was undertaken to clarify the relative efficacy of mAbs and oral therapies. Design: Two ITC methods that use individual patient data (IPD) to adjust for between-trial differences, PS analyses and simulated treatment comparisons (STCs), were used to compare the mAb ofatumumab versus the oral therapies cladribine, fingolimod, and ozanimod. Data sources and methods: As IPD were available for trials of ofatumumab and fingolimod, PS analyses were conducted. Given summary-level data were available for cladribine, fingolimod, and ozanimod trials, STCs were conducted between ofatumumab and each of these oral therapies. Three efficacy outcomes were compared: annualized relapse rate (ARR), 3-month confirmed disability progression (3mCDP), and 6-month CDP (6mCDP). Results: The PS analyses demonstrated ofatumumab was statistically superior to fingolimod for ARR and time to 3mCDP but not time to 6mCDP. In STCs, ofatumumab was statistically superior in reducing ARR and decreasing the proportion of patients with 3mCDP compared with cladribine, fingolimod, and ozanimod and in decreasing the proportion with 6mCP compared with fingolimod and ozanimod. These findings were largely consistent with recently published NMAs that identified mAb therapies as the most efficacious DMTs for RMS. Conclusion: Complementary ITC methods showed ofatumumab was superior to cladribine, fingolimod, and ozanimod in lowering relapse rates and delaying disability progression among patients with RMS. Our study supports the therapeutic superiority of mAbs over currently available oral DMTs for RMS and the delineation of mAbs as high-efficacy therapies.

01 Jan 2023·International Journal of Technology Assessment in Health Care

A systematic review of economic evaluations for RPE65-mediated inherited retinal disease including HTA assessment of broader value

Review

Author: Farris, Maria ; Goodall, Stephen ; De Abreu Lourenco, Richard

AbstractObjectiveTo summarize the key methodological challenges identified by health technology assessment (HTA) agencies assessing gene therapy (GT) and consideration of broad elements of value.MethodEconomic evaluations (EEs) of voretigene neparvovec (VN) in RPE65-mediated inherited retinal disease (IRD) published in English were selected. HTA evaluations from Australia, Canada, Ireland, Scotland, England, and the United States were reviewed. An existing methodological framework was used to identify the challenges and considerations.ResultsEight unique EEs were identified of which six were evaluated by HTA agencies. Incremental cost-effectiveness ratios ranged from $68,951 to $643,813 per quality-adjusted life-years (QALY) gained (healthcare perspective) and dominant to $480,130 per QALY gained (societal perspective). The key challenges were the lack of validated surrogate outcome, utility values and indirect costs from IRD patients, and limited evidence of the long-term treatment effect. Two HTA agencies reviewed a range of novel broader elements of value and whether they were associated with VN while other agencies discussed some elements of broader value. Caregiver disutility was included in some, but not all, evaluations.ConclusionThe methodological challenges were consistent with innovative interventions for rare diseases and managed using standard methods. Broader value was important to decision-makers but inconsistently applied across agencies. Possible reasons are limitations in the evidence available of the broader benefits that VN offers and how to incorporate these within an EE. A need exists for greater guidance and consistency across jurisdictions regarding the consideration of broader value that considers latest best practice.

100 Deals associated with Novartis Pharmaceuticals Australia Pty Ltd.

Login to view more data

100 Translational Medicine associated with Novartis Pharmaceuticals Australia Pty Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

38

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Valsartan ( AT1R )	Hypertension More	Approved
Carbamazepine ( Sodium channels )	Epilepsy More	Approved
Secukinumab ( IL-17A )	Enthesitis-Related Arthritis More	Approved
Lutetium (177 Lu) Vipivotide Tetraxetan ( PSMA )	PSMA-Positive Castration-Resistant Prostatic Cancer More	Approved
Vildagliptin/Metformin Hydrochloride ( DPP-4 x PRKAB1 )	Diabetes Mellitus More	Approved